Pheochromocytomatosis Treated With Peptide Receptor Radionuclide Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 35020659.
- Also identified by DOI 10.1097/RLU.0000000000003973.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pheochromocytomatosis refers to pheochromocytoma tumorlets developed as a result of seeding of tumor cells around the surgical bed due to intraoperative tumor capsule rupture and tumor cell spillage. As pheochromocytomatosis is relatively rare, optimal management is not clear. We describe a 42-year-old man with progressive pheochromocytomatosis despite surgical debulking. He did not have a family history of pheochromocytoma or harbor mutations in pheochromocytoma-predisposing genes. The pheochromocytomatosis tumorlets exhibited uptake on DOTATATE PET. He underwent PRRT (peptide receptor radionuclide therapy), which stabilized the pheochromocytomatosis progression. This case highlights the rare phenomenon of pheochromocytomatosis and the utility of PRRT in treating it.
Medical subject headings
- Adrenal Gland Neoplasms
- Neuroendocrine Tumors
- Organometallic Compounds
- Pheochromocytoma